Select language:

New COVID-19 vaccine registered in Russia

 / Главная / Russkiy Mir Foundation / News / New COVID-19 vaccine registered in Russia

New COVID-19 vaccine registered in Russia


27.08.2021

Photo credit: mos.ru (CC BY 4.0)

Another vaccine against coronavirus has been registered in Russia, TASS reports. The EpiVacCorona-N jab was developed by the scientists of the Vector center.

The AURORA-CoV trademark is registered in Rospatent for the name of EpiVacCorona-N. It will be used as the name for the new generation of the EpiVacCorona vaccine. The Vector Center explained that the drug differs from the previous version of EpiVacCorona. While the active ingredients remain the same, the production technology has changed.

The shelf life of the drug is six months at a temperature of 2-8 degrees Celsius. The drug is indicated for use in adults from 18 to 60 years old.

According to Grigory Ivliev, who heads Rospatent, Russian developers have a comprehensive approach to the issue of vaccine protection. They patent not only the substance itself, but also lists of ingredients, methods of application, production of individual components, as well as various forms of the vaccine.

Russkiy Mir

News by subject

Publications

U.S. Republican senators have uncovered a secret Soviet agent sent to the United States back in 1991 to undermine the banking system there. This is the conclusion that can be drawn from the media buzz. It followed the Senate Banking Committee’s questioning of Professor Saule Omarova, Joe Biden's nominee for the top position in the U.S. Government Accountability Office, last week.
The Linguistics Forum 2021: Language Policy and Language Preservation was held at the Institute of Linguistic Research of the Russian Academy of Sciences in Moscow. How to preserve Russia's linguistic diversity amid the global decline in the number of languages? Director of the Institute of Linguistic Research of the Russian Academy of Sciences and linguist Andrej Kibrik has the answer.